15th Mar 2019 17:44
Horizon Discovery Group plc
15 March 2019
Horizon Discovery Group plc
Director/PDMR Shareholding
Cambridge, UK, 15 March 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that 70,730 options were granted today over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to Terry Pizzie, CEO, in accordance with the Company's Long Term Incentive Plan. The options have an exercise price of 1 pence per share and will vest equally on each of the second and third anniversaries of the grant date.
The options granted are equivalent to 0.047% of the Company's existing issued share capital.
ENDS
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Jayesh Pankhania, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Email: [email protected]
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Terry Pizzie | |
2 | Reason for the notification | ||
a) | Position/status | Chief Executive Officer - PDMR | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Horizon Discovery Group plc | |
b) | Legal Entity Identifier | 213800L812B9NI5M3G89 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument Identification code | Options over ordinary shares of 1.0 pence each GB00BK8FL363 | |
b) | Nature of the transaction | Grant of Options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Exercise Price | No. of shares |
£0.01 | 70,730
| ||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
n/a | |
f) | Date of the transaction | 15 March 2019 | |
g) | Place of the transaction | Off market | |
Related Shares:
HZD.L